Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Concept/Terms
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Antineoplastic Drug Resistance
- Drug Resistance, Antineoplastic
- Resistance, Antineoplastic Drug
- Resistance, Antineoplastic Agent
- Antineoplastic Agent Resistance
- Neoplasm Drug Resistance
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in Harvard Catalyst Profiles by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 4 | 5 |
| 1996 | 1 | 3 | 4 |
| 1997 | 1 | 2 | 3 |
| 1998 | 5 | 4 | 9 |
| 1999 | 0 | 9 | 9 |
| 2000 | 3 | 6 | 9 |
| 2001 | 2 | 15 | 17 |
| 2002 | 9 | 18 | 27 |
| 2003 | 14 | 19 | 33 |
| 2004 | 13 | 28 | 41 |
| 2005 | 15 | 35 | 50 |
| 2006 | 15 | 37 | 52 |
| 2007 | 27 | 48 | 75 |
| 2008 | 34 | 37 | 71 |
| 2009 | 34 | 51 | 85 |
| 2010 | 46 | 49 | 95 |
| 2011 | 47 | 50 | 97 |
| 2012 | 43 | 68 | 111 |
| 2013 | 57 | 72 | 129 |
| 2014 | 78 | 81 | 159 |
| 2015 | 109 | 71 | 180 |
| 2016 | 97 | 90 | 187 |
| 2017 | 77 | 104 | 181 |
| 2018 | 89 | 97 | 186 |
| 2019 | 88 | 97 | 185 |
| 2020 | 86 | 96 | 182 |
| 2021 | 69 | 69 | 138 |
| 2022 | 9 | 32 | 41 |
| 2023 | 0 | 3 | 3 |
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cells. Commun Biol. 2023 Jan 18; 6(1):65.
-
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nat Commun. 2023 Jan 17; 14(1):252.
-
Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer. J Clin Invest. 2023 Jan 17; 133(2).
-
In Silico Identification and In Vitro Evaluation of New ABCG2 Transporter Inhibitors as Potential Anticancer Agents. Int J Mol Sci. 2022 Dec 31; 24(1).
-
Line by Line: Distinct Patterns of Anti-EGFR Antibody Resistance by Line of Therapy. J Clin Oncol. 2023 Jan 20; 41(3):436-438.
-
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer. Cancer Discov. 2022 11 02; 12(11):2666-2683.
-
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer. Cancer Res. 2022 11 02; 82(21):4079-4092.
-
Reply to Correspondence on "Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase". Angew Chem Int Ed Engl. 2022 11 14; 61(46):e202209518.
-
Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia. Br J Haematol. 2023 Feb; 200(3):323-328.
-
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. Cancer Res. 2022 10 17; 82(20):3673-3686.